RT Journal Article
SR Electronic
T1 Prior SARS-CoV-2 Infection and COVID-19 Vaccine Effectiveness against Outpatient Illness during Widespread Circulation of SARS-CoV-2 Omicron Variant, US Flu VE Network
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.01.10.23284397
DO 10.1101/2023.01.10.23284397
A1 Tartof, Sara Y.
A1 Xie, Fagen
A1 Yadav, Ruchi
A1 Wernli, Karen J.
A1 Martin, Emily T.
A1 Belongia, Edward A.
A1 Gaglani, Manjusha
A1 Zimmerman, Richard K.
A1 Talbot, H. Keipp
A1 Thornburg, Natalie
A1 Flannery, Brendan
A1 Chung, Jessie R.
A1 US Flu VE Network Investigators
YR 2023
UL http://medrxiv.org/content/early/2023/01/11/2023.01.10.23284397.abstract
AB Background We estimated combined protection conferred by prior SARS-CoV-2 infection and COVID-19 vaccination against COVID-19-associated acute respiratory illness (ARI).Methods During SARS-CoV-2 Delta (B.1.617.2) and Omicron (B.1.1.529) variant circulation between October 2021 and April 2022, prospectively enrolled adult patients with outpatient ARI had respiratory and filter paper blood specimens collected for SARS-CoV-2 molecular testing and serology. Dried blood spots were tested for immunoglobulin-G antibodies against SARS-CoV-2 nucleocapsid (NP) and spike protein receptor binding domain antigen using a validated multiplex bead assay. Evidence of prior SARS-CoV-2 infection also included documented or self-reported laboratory-confirmed COVID-19. We used documented COVID-19 vaccination status to estimate vaccine effectiveness (VE) by multivariable logistic regression by prior infection status.Results 455 (29%) of 1577 participants tested positive for SARS-CoV-2 infection at enrollment; 209 (46%) case-patients and 637 (57%) test-negative patients were NP seropositive, had documented previous laboratory-confirmed COVID-19, or self-reported prior infection. Among previously uninfected patients, three-dose VE was 97% (95% confidence interval [CI], 60%– 99%) against Delta, but not statistically significant against Omicron. Among previously infected patients, three-dose VE was 57% (CI, 20%–76%) against Omicron; VE against Delta could not be estimated.Conclusions Three mRNA COVID-19 vaccine doses provided additional protection against SARS-CoV-2 Omicron variant-associated illness among previously infected participants.Competing Interest StatementAll authors completed an ICJME form for disclosure of potential conflicts of interest. Dr. Gaglani reports grants from CDC-Abt, CDC-Vanderbilt, and CDC-Westat. Dr. Martin reports grants from Merck. Dr. Zimmerman reports grants from Sanofi Pasteur. All other authors report no potential conflicts of interest.Funding StatementThis work was supported by Centers for Disease Control grant numbers 75D30121C11529, 75D30121C12339, 75D30121C12246, 75D30121C11513, 75D30121C12279, 75D30121C11909, 75D30121C11519, National Institutes of Health grant number UL1TR001857, and National Center for Advancing Translational Sciences Clinical Translational Science Award number 5UL1TR002243-03.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRBs of Kaiser Permanente Southern California, Kaiser Permanente Washington, University of Michigan, Henry Ford Medical Center, Marshfield Clinic Research Institute, Baylor Scott & White Health, University of Pittsburgh, Vanderbilt University, US Centers for Disease Control and Prevention gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the corresponding author.